Ron Rabinowicz

Ron Rabinowicz

Auto-generated profile, based on publicly available information

Ron Rabinowicz

Department of Pediatric Hematology/Oncology Schneider Children's Medical Center Petah Tikva Israel

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
DWDerek Wong
Derek Wong
PLPing Luo
Ping Luo
LOLeslie E. Oldfield
Leslie E. Oldfield
HGHaifan Gong
Haifan Gong
LBLedia Brunga
Ledia Brunga
TPTrevor J Pugh
Trevor J Pugh
People with Li–Fraumeni syndrome (LFS) harbor a germline pathogenic variant in the TP53 tumor suppressor gene, face a near 100% lifetime risk of cancer, and routinely undergo intensive surveillance protocols. Liquid biopsy has become an attractive tool for a range of clinical applications, including early cancer detection. Here, we provide a proof-of-principle for a multimodal liquid biopsy assay that integrates a targeted gene panel, shallow whole-genome, and cell-free methylated DNA immunoprecipitation sequencing for the early detection of cancer in a longitudinal cohort of 89 LFS patients. Multimodal analysis increased our detection rate in patients with an active cancer diagnosis over uni-modal analysis and was able to detect cancer-associated signal(s) in carriers prior to diagnosis with conventional screening (positive predictive value = 67.6%, negative predictive value = 96.5%). Although adoption of liquid biopsy into current surveillance will require further clinical validation, this study provides a framework for individuals with LFS. Significance: By utilizing an integrated cell-free DNA approach, liquid biopsy shows earlier detection of cancer in patients with LFS compared with current clinical surveillance methods such as imaging. Liquid biopsy provides improved accessibility and sensitivity, complementing current clinical surveillance methods to provide better care for these patients. See related commentary by Latham et al., p. 23. This article is featured in Selected Articles from This Issue, p. 5

3 September 2024 in Journal of Medical Internet Research
Verified
Journal Article
Open access
SGSarah M Goodday
Sarah M Goodday
EKEmma Karlin
Emma Karlin
ABAlexa Brooks
Alexa Brooks
CCCarol Chapman
Carol Chapman
CHChristiana Harry
Christiana Harry
SFStephen H Friend
Stephen H Friend
Background: Wearable digital health technologies and mobile apps (personal digital health technologies [DHTs]) hold great promise for transforming health research and care. However, engagement in personal DHT research is poor. Objective: The objective of this paper is to describe how participant engagement techniques and different study designs affect participant adherence, retention, and overall engagement in research involving personal DHTs. Methods: Quantitative and qualitative analysis of engagement factors are reported across 6 unique personal DHT research studies that adopted aspects of a participant-centric design. Study populations included (1) frontline health care workers; (2) a conception, pregnant, and postpartum population; (3) individuals with Crohn disease; (4) individuals with pancreatic cancer; (5) individuals with central nervous system tumors; and (6) families with a Li-Fraumeni syndrome affected member. All included studies involved the use of a study smartphone app that collected both daily and intermittent passive and active tasks, as well as using multiple wearable devices including smartwatches, smart rings, and smart scales. All studies included a variety of participant-centric engagement strategies centered on working with participants as co-designers and regular check-in phone calls to provide support over study participation. Overall retention, probability of staying in the study, and median adherence to study activities are reported. Results: The median proportion of participants retained in the study across the 6 studies was 77.2% (IQR 72.6%-88%). The probability of staying in the study stayed above 80% for all studies during the first month of study participation and stayed above 50% for the entire active study period across all studies. Median adherence to study activities varied by study population. Severely ill cancer populations and postpartum mothers showed the lowest adherence to personal DHT research tasks, largely the result of physical, mental, and situational barriers. Except for the cancer and postpartum populations, median adherences for the Oura smart ring, Garmin, and Apple smartwatches were over 80% and 90%, respectively. Median adherence to the scheduled check-in calls was high across all but one cohort (50%, IQR 20%-75%: low-engagement cohort). Median adherence to study-related activities in this low-engagement cohort was lower than in all other included studies. Conclusions: Participant-centric engagement strategies aid in participant retention and maintain good adherence in some populations. Primary barriers to engagement were participant burden (task fatigue and inconvenience), physical, mental, and situational barriers (unable to complete tasks), and low perceived benefit (lack of understanding of the value of personal DHTs). More population-specific tailoring of personal DHT designs is needed so that these new tools can be perceived as personally valuable to the end user.

11 April 2022 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
RRRon Rabinowicz
Ron Rabinowicz
BMBryan Maguire
Bryan Maguire
JHJohann Hitzler
Johann Hitzler
APAngela Punnett
Angela Punnett

27 June 2013 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
LBLina Berkun
Lina Berkun
RRRon Rabinowicz
Ron Rabinowicz
MBMicha Barchana
Micha Barchana
ILIrena Liphshiz
Irena Liphshiz
SLShai Linn
Shai Linn
Myriam Weyl Ben-ArushMyriam Weyl Ben-Arush
Myriam Weyl Ben-Arush

11 August 2025 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
ASAviv Sever
Aviv Sever
RRRon Rabinowicz
Ron Rabinowicz
SBShlomit Barzilai-Birenboim
Shlomit Barzilai-Birenboim
SFSalvador Fisher
Salvador Fisher
RLRonit Goldman Levi
Ronit Goldman Levi
VYVered Yahalom
Vered Yahalom
Background: Granulocyte transfusions (GTXs) are used in neutropenic pediatric hemato‐oncology patients with infections unresponsive to antimicrobial therapy, but their clinical benefit remains uncertain.Methods: We retrospectively reviewed all pediatric patients who received GTXs between 2013 and 2023 at a tertiary medical center. We assessed associations between GTX administration, absolute neutrophil count (ANC) increment, and C‐reactive protein (CRP) reduction as a surrogate marker of treatment response.Results: Forty‐nine patients received 312 GTXs across 56 episodes: 47 for therapeutic use during active infection and nine for secondary prophylaxis. Higher ANC increments were observed after transfusions containing ≥0.6 × 10⁹ neutrophils/kg from same‐day collections. ANC rises were transient, typically declining within 24 hours. CRP levels decreased significantly after the first GTX (p = 0.001) and more markedly by the end of treatment (p < 0.001). ANC increment was significantly associated with CRP reduction (p = 0.006). GTX‐related adverse events occurred in 3% of transfusions. Infection‐related mortality was 17% in the treatment group, while no severe infections occurred in the secondary prophylaxis group.Conclusions: GTXs appear to be a safe adjunctive therapy in high‐risk neutropenic children with severe infections. The observed correlation between ANC increment and CRP reduction supports a potential therapeutic effect and warrants further prospective evaluation.

24 October 2024 in Blood
Verified
Journal Article
Closed access
RRRon Rabinowicz
Ron Rabinowicz
SIShai Izraeli
Shai Izraeli